EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation

Katharina Fleischhauer iD, Cristina Toffalori iD, Federica Cugnata iD, Jan A Hofmann, Giorgio Orofino iD, Francesca Lorentino, Müberra Ahci-Hanci, Vinzenz Lange iD, Carlheinz R Müller iD, Desiree Kunadt iD, Martin Bornhäuser iD, Guillermo Sanz iD und 39 weitere

Journal of Clinical Oncology · 10.08.2026 · 44 (23) · 2221-2232

DOI: 10.1200/jco-26-00113 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2026. Verfasst von Katharina Fleischhauer und 50 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Cellular Therapy, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Donor Selection, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, HLA Antigens. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE For patients with hematologic malignancies, relapse is the leading cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). Frequently, relapses are explained by immune evasion through alterations of human leukocyte antigens (HLAs), but determinants and clinical consequences remain poorly defined. METHODS We analyzed 533 relapses of hematologic cancers after allo-HCT from different donor types, conducted at 27 centers worldwide. Genomic loss of mismatched HLA (HLA loss) was assessed using a newly developed next-generation sequencing pipeline. Clinical and immunogenetic factors associated with HLA loss were evaluated. Using HLA data from approximately 5 million individuals, a web-based tool to infer HLA incompatibility phasing was developed. RESULTS HLA loss occurred in 15.6% of relapses, with significant variation according to donor type (28.7% haploidentical family, 7.2% unrelated adult, 2.7% cord blood, P < .0001). The distribution of HLA mismatches across the patient's haplotypes, predicted through the phasing tool, was strongly associated with HLA loss, with an incidence of 27.6% when HLA mismatches were in the same haplotype, compared with 5.4% if present on different haplotypes ( P < .0001). HLA loss affected postrelapse outcomes, abrogating the efficacy of original donor lymphocyte infusions, with significant survival advantage by second allo-HCT from a different donor. CONCLUSION The likelihood of HLA loss varies significantly according to the number and positioning of HLA mismatches between patient and donor. A newly developed phasing tool enables reliable prediction of its risk, supporting informed donor selection. Routine assessment of HLA loss at relapse is warranted, as it critically affects the success of immunologic salvage therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Donor SelectionHematologic NeoplasmsHematopoietic Stem Cell TransplantationHLA AntigensLeukemiaAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedYoung AdultHaplotypesHistocompatibility TestingRecurrenceTransplantation, Homologous

Substanzen

HLA Antigens

Autor:innen und Institutionen

  • Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
  • German Cancer Consortium, Partner Site Essen/Düsseldorf, Heidelberg, Germany.
  • Unit of Immunogenetics, Leukemia Genomics and Immunobiology, I.R.C.C.S. San Raffaele Scientific Institute, Milano, Italy.
  • University Centre for Statistics in the Biomedical Sciences (CUSSB), Vita-Salute San Raffaele University, Milan, Italy.
  • DKMS Group, Tübingen, Germany.
  • Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. San Raffaele Scientific Institute, Milano, Italy.

ORCID-Profile: Katharina Fleischhauer, Cristina Toffalori, Federica Cugnata, Giorgio Orofino, Vinzenz Lange, Carlheinz R Müller, Desiree Kunadt, Martin Bornhäuser, Guillermo Sanz, Robert Soiffer, Haris Ali, Kathrin Nachtkamp, Andrea Bacigalupo, Francesca Bonifazi, Leo Luznik, Arnon Nagler, Filippo Milano, Antonio Pierini, Mohamad Mohty, Neal Flomenberg, Akifumi Takaori-Kondo, Takanori Teshima, Marco Andreani, Maria Teresa Lupo Stanghellini, Monzr M Al Malki, Robert Zeiser, Robert Coleman Lindsley, Jaime Sanz, Dietrich Beelen, Friedrich Stölzel, Jürgen Sauter, Alexander H Schmidt, Luca Vago

Zitieren

APA

Fleischhauer, K., Toffalori, C., Cugnata, F., Hofmann, J. A., Orofino, G., Lorentino, F., Ahci-Hanci, M., Lange, V., Müller, C. R., Kunadt, D., Bornhäuser, M., Sanz, G., Soiffer, R., Waterhouse, M., Giaccone, L., Ali, H., Nachtkamp, K., Bacigalupo, A., Bonifazi, F., …, & HLALOSS Consortium (2026). Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 44(23), 2221-2232. https://doi.org/10.1200/jco-26-00113

Vancouver

Fleischhauer K, Toffalori C, Cugnata F, Hofmann JA, Orofino G, Lorentino F, et al. Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation. Journal of Clinical Oncology. 2026;44(23):2221-2232. doi:10.1200/jco-26-00113

BibTeX
@article{Fleischhauer2026,
  author = {Fleischhauer, Katharina and Toffalori, Cristina and Cugnata, Federica and Hofmann, Jan A and Orofino, Giorgio and Lorentino, Francesca and Ahci-Hanci, Müberra and Lange, Vinzenz and Müller, Carlheinz R and Kunadt, Desiree and Bornhäuser, Martin and Sanz, Guillermo and Soiffer, Robert and Waterhouse, Miguel and Giaccone, Luisa and Ali, Haris and Nachtkamp, Kathrin and Bacigalupo, Andrea and Bonifazi, Francesca and Luznik, Leo and Facchini, Luca and Bramanti, Stefania and Nagler, Arnon and Saccardi, Riccardo and Milano, Filippo and Zallio, Francesco and Pierini, Antonio and Mohty, Mohamad and Flomenberg, Neal and Takaori-Kondo, Akifumi and Vey, Norbert and Teshima, Takanori and Kröger, Nicolaus and Laperche, Carolina Martinez and Andreani, Marco and Lupo Stanghellini, Maria Teresa and Peccatori, Jacopo and Di Serio, Clelia and Kobbe, Guido and Al Malki, Monzr M and Bruno, Benedetto and Zeiser, Robert and Lindsley, Robert Coleman and Sanz, Jaime and Beelen, Dietrich and Stölzel, Friedrich and Sauter, Jürgen and Schmidt, Alexander H and Ciceri, Fabio and Vago, Luca and HLALOSS Consortium, HLALOSS Consortium},
  title = {Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {23},
  pages = {2221--2232},
  doi = {10.1200/jco-26-00113}
}
Kostenlos starten →